Clincosm LogoSign in Get a demo

PREDICT-PANC: Determining Individualized Cancer Therapy in Pancreatic Cancer

Sponsor
Medical College of Wisconsin (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05914987
Collaborator
(none)
1,000
Enrollment
1
Location
120
Anticipated Duration (Months)
8.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patients. Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well molecular testing might predicts response to therapy. Patient demographic and outcome parameters to be evaluated include, but are not limited to, tumor response, time to treatment failure, patient survival, and toxicity.

Condition or Disease Intervention/Treatment Phase
  • Other: Targeted Therapy

Study Design

Study Type:
Observational
Anticipated Enrollment :
1000 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Profile-Related Evidence Determining Individualized Cancer Therapy in Pancreatic Cancer (PREDICT-PANC)
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Aug 1, 2028
Anticipated Study Completion Date :
Aug 1, 2033

Outcome Measures

Primary Outcome Measures

  1. Number of Subjects Receiving Targeted Therapy [5 years]

    This measure is the number of study subject's whose treating physician prescribes and subsequently receives the therapeutic recommendation of the Molecular Tumor Board.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Age ≥18 years.

  • Pathologically confirmed pancreatic cancer.

  • Ability to understand a written informed consent document and the willingness to sign it

Exclusion Criteria:

  • Age <18 years.

  • Primary cancer diagnosis other than pancreatic cancer.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Froedtert Hospital and the Medical College of Wisconsin Milwaukee Wisconsin United States 53226

Sponsors and Collaborators

  • Medical College of Wisconsin

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mandana Kamgar, MD, Assistant Professor, Medical College of Wisconsin
ClinicalTrials.gov Identifier:
NCT05914987
Other Study ID Numbers:
  • PRO00048019
First Posted:
Jun 22, 2023
Last Update Posted:
Jun 22, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mandana Kamgar, MD, Assistant Professor, Medical College of Wisconsin
Mutation
Genomics
Targeted Therapy
Cancer
Pancreas
Additional relevant MeSH terms:
Pancreatic Neoplasms

Study Results

No Results Posted as of Jun 22, 2023